Oxford Biomedica (LON:OXB) Stock Crosses Below 200 Day Moving Average – Here’s Why

Oxford Biomedica plc (LON:OXB)’s stock price passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of GBX 663.38 and traded as low as GBX 544. Oxford Biomedica shares last traded at GBX 560, with a volume of 11,794,788 shares.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on OXB. Jefferies Financial Group assumed coverage on shares of Oxford Biomedica in a report on Monday, March 23rd. They issued a “buy” rating and a GBX 827 price objective for the company. Stifel Nicolaus reiterated a “buy” rating and issued a GBX 950 price target on shares of Oxford Biomedica in a research report on Wednesday, March 11th. Finally, Deutsche Bank Aktiengesellschaft boosted their price target on Oxford Biomedica from GBX 735 to GBX 800 and gave the company a “buy” rating in a research note on Friday, January 9th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of GBX 687.

Oxford Biomedica Stock Performance

The company has a current ratio of 2.20, a quick ratio of 1.67 and a debt-to-equity ratio of 116.74. The company has a market cap of £676.88 million, a P/E ratio of -15.46 and a beta of 1.04. The company has a 50 day moving average price of GBX 702.33 and a 200-day moving average price of GBX 663.15.

Oxford Biomedica (LON:OXB) last released its quarterly earnings data on Thursday, March 26th. The biopharmaceutical company reported GBX (26.92) earnings per share for the quarter. Oxford Biomedica had a negative net margin of 17.85% and a negative return on equity of 48.56%. On average, equities analysts expect that Oxford Biomedica plc will post -31.0799998 earnings per share for the current fiscal year.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.